MRUS - Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)
2024-05-24 13:00:44 ET
Summary
- Merus N.V. is experiencing significant growth and entering a higher price territory, making the risk-reward less clear.
- The company's bispecific antibody, petosemtamab, showed promising results in a phase 2 study for head and neck squamous cell carcinoma.
- Merus' other bispecific antibody, zenocutuzumab, has a high chance of approval for NRG1-positive NSCLC and pancreatic cancer, with a decision expected later in 2024.
Topline Summary and Update
When I first covered Merus N.V. ( MRUS ), a cancer-focused biotech based in the Netherlands, I was rather sanguine about their prospects heading into 2024. They are on the fast track to get a drug approval, and their EGFR-targeted bispecific just got a huge publication of data coming out of this year's ASCO Annual Meeting....
Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)